DE69638326D1 - Azelluläre Pertussis-Impfstoffe und Verfahren zu deren Herstellung - Google Patents

Azelluläre Pertussis-Impfstoffe und Verfahren zu deren Herstellung

Info

Publication number
DE69638326D1
DE69638326D1 DE69638326T DE69638326T DE69638326D1 DE 69638326 D1 DE69638326 D1 DE 69638326D1 DE 69638326 T DE69638326 T DE 69638326T DE 69638326 T DE69638326 T DE 69638326T DE 69638326 D1 DE69638326 D1 DE 69638326D1
Authority
DE
Germany
Prior art keywords
pref
iii
pertussis
toxoid
agg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69638326T
Other languages
English (en)
Inventor
John R Vose
Raafat E Fahim
Gail E D Jackson
Larry U L Tan
Andrew Herbert
Leslie Boux
Luis Barreto
John Thipphawong
Michael H Klein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur Ltd
Original Assignee
Sanofi Pasteur Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/433,646 external-priority patent/US5877298A/en
Application filed by Sanofi Pasteur Ltd filed Critical Sanofi Pasteur Ltd
Application granted granted Critical
Publication of DE69638326D1 publication Critical patent/DE69638326D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/235—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Bordetella (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55544—Bacterial toxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69638326T 1995-05-04 1996-05-02 Azelluläre Pertussis-Impfstoffe und Verfahren zu deren Herstellung Expired - Lifetime DE69638326D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/433,646 US5877298A (en) 1995-05-04 1995-05-04 Acellular pertussis vaccines and methods of preparing thereof
US50174395A 1995-07-12 1995-07-12

Publications (1)

Publication Number Publication Date
DE69638326D1 true DE69638326D1 (de) 2011-03-10

Family

ID=27029924

Family Applications (3)

Application Number Title Priority Date Filing Date
DE69625191T Expired - Lifetime DE69625191T2 (de) 1995-05-04 1996-05-02 Azelluläre pertussis impfstoffe und verfahren zur herstellung
DE69622555T Expired - Lifetime DE69622555T2 (de) 1995-05-04 1996-05-02 Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung
DE69638326T Expired - Lifetime DE69638326D1 (de) 1995-05-04 1996-05-02 Azelluläre Pertussis-Impfstoffe und Verfahren zu deren Herstellung

Family Applications Before (2)

Application Number Title Priority Date Filing Date
DE69625191T Expired - Lifetime DE69625191T2 (de) 1995-05-04 1996-05-02 Azelluläre pertussis impfstoffe und verfahren zur herstellung
DE69622555T Expired - Lifetime DE69622555T2 (de) 1995-05-04 1996-05-02 Azelluläre pertussis-impfstoffe und verfahren zu deren herstellung

Country Status (18)

Country Link
US (1) US6399076B2 (de)
EP (7) EP1233022B1 (de)
CN (2) CN1198099A (de)
AT (3) ATE496634T1 (de)
AU (2) AU715417B2 (de)
BR (2) BR9608115A (de)
CA (3) CA2220063C (de)
DE (3) DE69625191T2 (de)
DK (3) DK1393744T3 (de)
ES (2) ES2182971T3 (de)
FR (1) FR16C0015I2 (de)
HK (1) HK1016191A1 (de)
LU (1) LU93036I2 (de)
MX (1) MX9708481A (de)
NL (1) NL300804I2 (de)
NZ (2) NZ306392A (de)
PT (3) PT824358E (de)
WO (2) WO1996034623A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2646776B1 (fr) * 1989-05-12 1994-06-03 Pasteur Institut Utilisation de preparations vaccinantes a base d'adenyl cyclase ou de bacteries les produisant en tant qu'antigenes protecteurs contre les effets des bordetella
DE69511392T2 (de) * 1994-04-28 2000-03-23 Takeda Chemical Industries Ltd Verfahren zur trennung von protektiven verbindungen aus bordetella pertussis
US6696065B1 (en) * 1995-05-04 2004-02-24 Aventis Pastuer Limited Acellular pertussis vaccines and methods of preparation thereof
GB9611501D0 (en) * 1996-06-03 1996-08-07 Smithkline Beecham Biolog Vaccine compositions
EP1762246A1 (de) * 1996-07-02 2007-03-14 Sanofi Pasteur Limited Vielwertige DTP-Polio-Impfstoffe
KR100649286B1 (ko) * 1998-10-21 2006-11-24 샤단호칭키타사토겐큐쇼 감독화톡신을 포함하는 백신제제
US8299210B2 (en) * 2003-11-20 2012-10-30 Sanofi Pasteur Methods for purifying pertussis toxin and peptides useful therefor
MX2007007288A (es) * 2004-12-17 2008-02-25 Nvi Nl Vaccininst Desacilacion de lps en bacterias gram negativas.
WO2008039171A2 (en) * 2005-08-08 2008-04-03 Oregon Health & Science University Inactivating pathogens with hydrogen peroxide for vaccine production
EP1867638A1 (de) * 2006-06-16 2007-12-19 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Verfahren zur kovalenten Verknüpfung zweier Moleküle mittels Diels-Alder-Reaktion mit inversem Elektronenbedarf
AU2007293673B2 (en) 2006-09-07 2013-06-27 Glaxosmithkline Biologicals S.A. Vaccine
CN100537767C (zh) * 2007-04-29 2009-09-09 中国药品生物制品检定所 百日咳疫苗保护性抗原的重组表达及其应用
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US20100330158A1 (en) * 2009-03-31 2010-12-30 Innopharma, Llc Protein-assisted drug delivery system for the targeted administration of active agents
US8574589B2 (en) 2009-05-11 2013-11-05 Novartis Ag Antigen purification process for pertactin antigen
CN103814048A (zh) * 2011-09-20 2014-05-21 生物辐射实验室股份有限公司 从生物分子制剂中去除杀病毒剂
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
CN102584958A (zh) * 2012-02-08 2012-07-18 北京天坛生物制品股份有限公司 百日咳杆菌69kd外膜蛋白的纯化方法
CN102793915B (zh) * 2012-07-25 2013-10-23 天津康希诺生物技术有限公司 一种无细胞百日咳疫苗的生产方法
DK2863943T3 (en) * 2013-03-08 2016-11-07 Janssen Vaccines & Prevention Bv acellular pertussis vaccines
KR102566292B1 (ko) 2015-06-05 2023-08-10 더블유.알. 그레이스 앤드 캄파니-콘. 흡착성 바이오프로세싱 정화제와 이의 제조 및 사용 방법
CN105106947A (zh) * 2015-07-21 2015-12-02 华兰生物工程股份有限公司 过氧化氢脱毒的无细胞百日咳疫苗及其制备方法
US11602559B2 (en) 2016-10-03 2023-03-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV-1 Env fusion peptide immunogens and their use
WO2018081832A1 (en) 2016-10-31 2018-05-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Peptide fragments from filoviruses and their uses
US11235056B2 (en) 2017-03-24 2022-02-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Glycan-masked engineered outer domains of HIV-1 gp120 and their use
KR102426041B1 (ko) * 2017-08-01 2022-07-29 주식회사 녹십자 냉동 및 해동 과정을 포함하는 백일해균 유래 단백질 수득 방법
US11136356B2 (en) 2017-10-16 2021-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant HIV-1 envelope proteins and their use
US20210353740A1 (en) 2018-09-23 2021-11-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Servic Hiv-1 env fusion peptide nanoparticle carrier conjugates and their use
AU2019368218A1 (en) 2018-10-22 2021-05-27 New York University Recombinant GP120 protein with V1-loop deletion
CN110358802B (zh) * 2019-08-16 2021-06-18 长春百克生物科技股份公司 一种去除百日咳组分菌毛蛋白2/3内毒素的方法
CN112094354B (zh) * 2020-11-05 2021-02-02 苏州世诺生物技术有限公司 副鸡禽杆菌基因工程亚单位疫苗、其制备方法及应用
EP4380613A1 (de) 2021-08-03 2024-06-12 The United States of America, as represented by the Secretary, Department of Health and Human Services Hiv-1 impfung und samt-247 microbizid zur vorbeugung von hiv-1 infektion
WO2023192835A1 (en) 2022-03-27 2023-10-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Base-covered hiv-1 envelope ectodomains and their use

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4258029A (en) 1979-04-23 1981-03-24 Connaught Laboratories Limited Synthetic adjuvants for stimulation of antigenic responses
DE3521994A1 (de) 1985-06-20 1987-01-02 Bayer Ag N-(2-aminoacylamido-2-desoxy-hexosyl)-amide-, -carbamate und -harnstoffe, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
GB8601279D0 (en) * 1986-01-20 1986-02-26 Public Health Lab Service Purification of pertussis antigens
US4705686A (en) 1986-05-09 1987-11-10 American Cyanamid Process for the preparation of acellular Bordetalla pertussis vaccine
WO1989001976A1 (en) * 1987-09-04 1989-03-09 Amgen Inc. Recombinant dna-derived bordetella toxin subunit analogs
GB8727489D0 (en) 1987-11-24 1987-12-23 Connaught Lab Detoxification of pertussis toxin
GB8807860D0 (en) 1988-04-05 1988-05-05 Connaught Lab Pertussis vaccine
US4967176A (en) * 1988-07-15 1990-10-30 Raychem Corporation Assemblies of PTC circuit protection devices
US5101014A (en) 1989-02-10 1992-03-31 United States Of America Process for the purification of a 69,000 da outer membrane protein of Bordetella pertussis
EP0474646A4 (en) * 1989-03-31 1992-10-21 Washington University Bordetella vaccines
US5276142A (en) 1989-12-11 1994-01-04 American Cyanamid Company Process for purification of a 69000 dalton antigenic protein from Bordetella pertussis
GB9007657D0 (en) * 1990-04-04 1990-05-30 Connaught Lab Purification of a pertussis outer membrane protein(omp69)
EP0484621A3 (en) * 1990-07-11 1992-08-26 American Cyanamid Company Efficacious vaccines against bordetella pertussis comprising a combination of individually purified pertussis antigens
DE69511392T2 (de) * 1994-04-28 2000-03-23 Takeda Chemical Industries Ltd Verfahren zur trennung von protektiven verbindungen aus bordetella pertussis
FR2728170A1 (fr) * 1994-12-15 1996-06-21 Pasteur Institut Vaccin de type acellulaire anti-bordetella
US5877298A (en) * 1995-05-04 1999-03-02 Connaught Lab Acellular pertussis vaccines and methods of preparing thereof

Also Published As

Publication number Publication date
BR9608114A (pt) 2000-10-31
EP1393744A1 (de) 2004-03-03
CA2220048A1 (en) 1996-11-07
EP1405643A1 (de) 2004-04-07
DK0824358T3 (da) 2003-01-27
AU715417B2 (en) 2000-02-03
CA2220063A1 (en) 1996-11-07
DK0826001T3 (da) 2002-11-18
DE69622555D1 (de) 2002-08-29
EP1234579A1 (de) 2002-08-28
DE69625191T2 (de) 2003-07-10
WO1996034623A1 (en) 1996-11-07
ES2182971T3 (es) 2003-03-16
CA2433502A1 (en) 1996-11-07
US20010009666A1 (en) 2001-07-26
BR9608115A (pt) 2004-07-13
EP0826001B1 (de) 2002-07-24
CN1193324A (zh) 1998-09-16
FR16C0015I1 (de) 2016-06-10
ATE228851T1 (de) 2002-12-15
US6399076B2 (en) 2002-06-04
EP1393744B1 (de) 2011-01-26
EP1233022B1 (de) 2015-12-09
ATE221081T1 (de) 2002-08-15
PT826001E (pt) 2002-12-31
AU5494196A (en) 1996-11-21
HK1016191A1 (en) 1999-10-29
MX9708481A (es) 1998-02-28
ATE496634T1 (de) 2011-02-15
ES2180758T3 (es) 2003-02-16
AU5494096A (en) 1996-11-21
EP0824358B1 (de) 2002-12-04
PT824358E (pt) 2003-02-28
WO1996034883A1 (en) 1996-11-07
FR16C0015I2 (fr) 2017-06-09
NZ306392A (en) 1999-04-29
CN100387618C (zh) 2008-05-14
DK1393744T3 (da) 2011-05-30
EP0826001A1 (de) 1998-03-04
NL300804I2 (de) 2016-11-01
EP0824358A1 (de) 1998-02-25
DE69622555T2 (de) 2003-03-27
NZ306391A (en) 1999-03-29
EP1233022A1 (de) 2002-08-21
AU710538B2 (en) 1999-09-23
CN1198099A (zh) 1998-11-04
PT1393744E (pt) 2011-05-03
LU93036I2 (fr) 2016-06-21
CA2220048C (en) 2006-03-07
CA2220063C (en) 2003-08-26
DE69625191D1 (de) 2003-01-16
EP1234580A1 (de) 2002-08-28

Similar Documents

Publication Publication Date Title
NL300804I2 (de)
AU4267093A (en) Vaccine compositions for mucosal delivery
RU99101850A (ru) Поливалентные ассоциированные коклюшно-дифтерийно-столбнячно(акдс)-полиомиелитные вакцины
AU649700B2 (en) Filamentous hemagglutinin of bordetella pertussis as a carrier molecule for conjugate vaccines
SI9720050B (en) Multivalent dtp-polio vaccines
AU710475B2 (en) Acellular pertussis vaccine with diphtheria- and tetanus-toxoids
LU91155I2 (fr) Combinaison d'anatoxine diphtérique, d'anatoxine tétanique, d'anatoxine coquelucheuse, d'hémagglutininine filamenteuse, de pertactine, d'agglutinogènes fimbriaux coquelucheux 2 et 3 et de virus poliomyélitique inactivé type 1, type 2 et type 3.
EP0761230A3 (de) Aus Bordetella pertussis Aussenmembranprotein enthaltender Impfstoffe und Verfahren zu seiner Herstellung
CA2224309A1 (en) Multivalent bovine coronavirus vaccine and method of treating bovine coronavirus infection
AU5625796A (en) Protective epitopes of adenyl cyclase-haemolysin(AC-Hly), their application to the treatment or to the prevention of bordetella infections
US8623380B2 (en) Acellular pertussis vaccine with diphthriae- and tetanus-toxoids
WO1997046255A3 (en) Vaccine composition comprising outer membrane protein fragments of bordetella pertussis
Mauro et al. Further observations on a dipheheria-tetanus vaccine adult type.
MXPA99004278A (es) Vacuna de pertusis acelular con toxoides de difteria y tetanos